As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

The regulation and remodeling of the tumor microenvironment (TME) are closely associated with how cancers typically progress ...

Due to these and other advances, the overall five-year survival rate for breast cancer is 96%, meaning that 96 out of every ...

They investigated whether allografts are sensitive to immune checkpoint blockade (ICB) using antibodies against programmed ...

The advent of large-scale sequencing in both development and disease has identified large numbers of candidate genes that may be linked to important phenotypes. Validating the function of these ...

Pacylex Pharmaceuticals Publishes a New Myristoylation Inhibitor Mechanism of Anti-Cancer Activity in Molecular Cancer Therapeutics ...

AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces that the Paris ...

This useful study reports that the exogenous expression of the microRNA miR-195 can partially compensate in early B cell development for the loss of EBF1, one of the key transcription factors in B ...

All grade interstitial lung disease (ILD) rates remained low with no new Grade 3 or higher ILD events observed. With multiple antibody drug conjugates (ADCs) approved during the course of the trial, ...